Carisma Therapeutics Launches First Human Trial for CAR-Monocyte Therapy

Carisma Therapeutics

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a significant milestone in cancer treatment. The company recently dosed the first patient in its Phase 1 clinical trial of CT-0525, an innovative gene-modified cellular therapy for solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).

“Dosing the first patient in the CT-0525 Phase 1 trial marks a critical step in developing engineered myeloid cells,” said Eugene P. Kennedy, M.D., Chief Medical Officer of Carisma. “This is the first time a CAR-Monocyte is tested in humans for solid tumors. Pre-clinical data suggests that our CAR-M platform can have a greater impact than our earlier CAR-Macrophage program. We anticipate faster manufacturing, higher dosing, and improved tumor infiltration. Initial data is expected by the end of 2024.”

Davendra Sohal, M.D., M.P.H., Professor of Medicine at the University of Cincinnati Cancer Center, emphasized the urgency of new treatments. “Patients with HER2-overexpressing solid tumors face limited options as their disease progresses. CT-0525 presents a novel approach with the potential to address this inadequacy. We are excited to be the first site to treat a patient with CT-0525 and aim to collaborate with other centers to expedite patient enrollment.”

The Phase 1 trial aims to assess the safety, tolerability, and manufacturing feasibility of CT-0525. The open-label study will enroll patients with locally advanced or metastatic HER2-positive solid tumors that have progressed despite standard therapies. The trial includes two dose-escalation cohorts.

Revolutionizing Cancer Treatment: Carisma Therapeutics’ Groundbreaking Trial

This trial represents a pioneering effort in cancer treatment. Traditional therapies often fall short for patients with advanced HER2-positive tumors. As these tumors resist standard treatments, new approaches are crucial.

READ:  STRATA Skin Sciences Publishes Promising Acne Therapy Study

CAR-Monocyte therapy involves modifying a patient’s immune cells to better recognize and attack cancer cells. Unlike earlier therapies, CAR-Monocytes may offer enhanced tumor penetration and persistence. If successful, this could revolutionize how we treat solid tumors, providing a new line of defense for patients with limited options.

For the broader medical community, the success of CT-0525 could pave the way for more advanced therapies using engineered myeloid cells. This would not only benefit HER2-positive cancer patients but could also extend to other types of tumors.

From an industry perspective, Carisma’s progress could set new standards in biotech innovation. The company’s ability to move from pre-clinical to human trials signifies robust scientific advancement and regulatory compliance. This milestone may attract further investment and partnerships, accelerating the development of similar therapies.

In conclusion, Carisma Therapeutics’ launch of the CT-0525 Phase 1 trial marks an important advance in cancer treatment. By pushing the boundaries of immunotherapy, the company aims to provide new hope for patients battling aggressive cancers. The medical community and investors alike will be watching closely as the trial progresses, anticipating a potential breakthrough in oncology.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.